secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-10-01T12:34:15+00:00
Accession:  0001628280-26-064117
Event type: leadership
Sentiment:  positive
Materiality: 0.62
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vir Biotechnology names Aziz Sawaf CFO effective October 5, 2026
----------------------------------------------------------------

- Vir named Aziz Sawaf EVP and CFO effective Oct. 5, 2026; Brent Sabatini ceases as interim principal financial officer, staying as SVP/Chief Accounting Officer.
- Sawaf, Theravance CFO since 2023 and ex-Gilead finance, gets $520,000 base salary, 45% target bonus, $150,000 sign-on.
- Equity grant around Nov. 15, 2026 includes options for 150,000 shares and 75,000 RSUs, each vesting over four years; option vests 25% on first anniversary then monthly.
- Under Vir's severance plan, a covered termination during the 12-month post-change-in-control period gives 12 months' salary plus target bonus, health benefits, and full equity acceleration.
- Outside that period, severance is nine months' salary plus pro-rated target bonus and up to nine months of health benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026064117/0001628280-26-064117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026064117/vir-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-064117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer